Historical Valuation
Briacell Therapeutics Corp (BCTX) is now in the Fair zone, suggesting that its current forward PS ratio of 6.41 is considered Fairly compared with the five-year average of -3.30. The fair price of Briacell Therapeutics Corp (BCTX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：7.13
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Briacell Therapeutics Corp (BCTX) has a current Price-to-Book (P/B) ratio of 1.35. Compared to its 3-year average P/B ratio of -8.86 , the current P/B ratio is approximately -115.28% higher. Relative to its 5-year average P/B ratio of 0.57, the current P/B ratio is about 139.08% higher. Briacell Therapeutics Corp (BCTX) has a Forward Free Cash Flow (FCF) yield of approximately -214.68%. Compared to its 3-year average FCF yield of -97.89%, the current FCF yield is approximately 119.31% lower. Relative to its 5-year average FCF yield of -62.90% , the current FCF yield is about 241.32% lower.
P/B
Median3y
-8.86
Median5y
0.57
FCF Yield
Median3y
-97.89
Median5y
-62.90
Competitors Valuation Multiple
AI Analysis for BCTX
The average P/S ratio for BCTX competitors is 7.45, providing a benchmark for relative valuation. Briacell Therapeutics Corp Corp (BCTX.O) exhibits a P/S ratio of 6.41, which is -13.92% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BCTX
1Y
3Y
5Y
Market capitalization of BCTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BCTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BCTX currently overvalued or undervalued?
Briacell Therapeutics Corp (BCTX) is now in the Fair zone, suggesting that its current forward PS ratio of 6.41 is considered Fairly compared with the five-year average of -3.30. The fair price of Briacell Therapeutics Corp (BCTX) is between to according to relative valuation methord.
What is Briacell Therapeutics Corp (BCTX) fair value?
BCTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Briacell Therapeutics Corp (BCTX) is between to according to relative valuation methord.
How does BCTX's valuation metrics compare to the industry average?
The average P/S ratio for BCTX's competitors is 7.45, providing a benchmark for relative valuation. Briacell Therapeutics Corp Corp (BCTX) exhibits a P/S ratio of 6.41, which is -13.92% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Briacell Therapeutics Corp (BCTX) as of Jan 09 2026?
As of Jan 09 2026, Briacell Therapeutics Corp (BCTX) has a P/B ratio of 1.35. This indicates that the market values BCTX at 1.35 times its book value.
What is the current FCF Yield for Briacell Therapeutics Corp (BCTX) as of Jan 09 2026?
As of Jan 09 2026, Briacell Therapeutics Corp (BCTX) has a FCF Yield of -214.68%. This means that for every dollar of Briacell Therapeutics Corp’s market capitalization, the company generates -214.68 cents in free cash flow.
What is the current Forward P/E ratio for Briacell Therapeutics Corp (BCTX) as of Jan 09 2026?
As of Jan 09 2026, Briacell Therapeutics Corp (BCTX) has a Forward P/E ratio of -0.63. This means the market is willing to pay $-0.63 for every dollar of Briacell Therapeutics Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Briacell Therapeutics Corp (BCTX) as of Jan 09 2026?
As of Jan 09 2026, Briacell Therapeutics Corp (BCTX) has a Forward P/S ratio of 6.41. This means the market is valuing BCTX at $6.41 for every dollar of expected revenue over the next 12 months.